Evidence map›Paper›PMID 40435176›Full record

ArticlePloS one2025

Identification of hub gene for the pathogenic mechanism and diagnosis of MASLD by enhanced bioinformatics analysis and machine learning.

Hong Lu, Ziyong Mao, Mengyao Zheng, Min Zhang, Heqing Huang, Yiling Chen, Long Lv, Zutao Chen

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hong LuInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Ziyong MaoBamRock Research Department, Suzhou BamRock Biotechnology Ltd., Suzhou, Jiangsu Province, China.
Mengyao ZhengCollege of Life Sciences, Qufu Normal University, Qufu, Shandong Province, China.
Min ZhangBamRock Research Department, Suzhou BamRock Biotechnology Ltd., Suzhou, Jiangsu Province, China.
Heqing HuangInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Yiling ChenInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
Long LvCentral Laboratory, The Affiliated Gaochun Hospital of Jiangsu University, Nanjing, Jiangsu Province, China.
Zutao ChenInfectious Disease Department, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.ORCID https://orcid.org/0009-0001-1488-1924

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous disease caused by multiple etiologies. It is characterized by excessive fat accumulation in the liver. Without intervention, MASLD can progress from steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and even to cirrhosis and hepatocellular carcinoma. However, the pathogenesis of MASH and the mechanism underlying the development of fibrosis remain poorly understood, posing challenges for accurate diagnosis of MASH and fibrosis. In this study, we analyzed tissue RNA-seq data and clinical information of healthy individuals and MASLD patients from multiple datasets, the key genes and pathways involved in the occurrence and progression of MASLD, MASH, and fibrosis were screened respectively. Our findings reveal that the development of MASLD, MASH and fibrosis is associated with lipid metabolism processes. Based on the RNA expression profiles of identified hub genes, we established three alternative diagnostic models for MASLD, MASH, and fibrosis. These models demonstrated excellent performance in the diagnosis of MASLD, MASH, and fibrosis, with AUC values exceeding 0.9, implicating its potential clinical values in disease diagnosis.

Indexed as

Computational BiologyFatty LiverMachine LearningGene Expression ProfilingHumansLipid MetabolismLiver Cirrhosis

Identifiers

PMID40435176
PMCPMC12118866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.